HK Stock Market Move | FUDANZHANGJIANG (01349) falls more than 4%, with a year-on-year net profit decrease of approximately 157 million yuan turning from profit to loss.

FUDANZHANGJIANG (01349) fell more than 4%, as of the time of writing, down 4.15% to 3 Hong Kong dollars, with a turnover of 7.522 million Hong Kong dollars. On the news front, on February 27, FUDANZHANGJIANG announced its 2025 performance report, with operating income of approximately 686 million yuan, a year-on-year decrease of 3.33%; the net loss attributable to the shareholders of the listed company was approximately 157 million yuan, a year-on-year change from profit to loss. During the reporting period, the group's production and operation were normal, and there were no major changes in the types of drugs sold on the market. Due to the inclusion of docetaxel liposome injection in the national centralized procurement catalog, the company's product Davot was not selected. According to the relevant centralized procurement rules and changes in the market competition landscape, the company made corresponding adjustments to the sales strategy of Davot during the reporting period, including but not limited to a gradual reduction in its market retail price from May 1, 2025, leading to a corresponding decrease in its profit margin.